Introduction {#S1}
============

As long as the pathophysiology of the FMS is not elucidated, the diagnosis ([@B197]; [@B5]) and the treatment ([@B114]) will remain inadequate. Many consider FMS to be psychosomatic ([@B102]) and there are still physicians who do not recognize the disorder. Although the name indicates a fibromuscular affection and the syndrome is classified as a rheumatic disorder, FMS is treated as a neurological problem, in accordance with the currently most accepted hypothesis: central sensitization ([@B175]). The history of FMS not only reveals the confusion ([@B73]) but also the importance of (1) inflammation, (2) a neuropathic type of pain, (3) referred pain after irritation or damage of the paraspinal ligaments, (4) increased substance P levels in cerebrospinal fluid (CSF), and (5) an etiology of trauma and/or infection accompanied by mental stress, which are all consistent with neuroinflammation. Female predominance and clustering with autoimmune diseases were recognized in the historical review ([@B73]), but suggestions of autoimmunity markers were omitted ([@B76]; [@B92]), despite being actual at the time of the review. Still, it seems that autoimmune susceptibility accompanies FMS. We propose that FMS is a neuropathy-induced autoimmune disease directed to nervous tissue. As autoimmunity is sex biased ([@B12]), the autoimmune hypothesis may explain the female prevalence observed in FMS.

The focus of the paper is to present the biological data from which this hypothesis emerges, followed by how it may explain central sensitization and the sleep alteration that characterize FMS. Next, we describe the mechanisms of immunological self-tolerance and how it can be breached, as well as the well-known sex differences in the immune system, which explains why women are more susceptible to develop certain autoimmunity disorders. We reflect on the complexities of proving the hypothesis and offer suggestions to verify the hypothesis.

Fibromyalgia: Introducing the Autoimmune Hypothesis {#S2}
===================================================

Fibromyalgia syndrome is characterized by unexplained chronic (\>3 months) widespread pain accompanied by moderate to severe sleep problems and/or fatigue ([@B5]). Fatigue upon awakening has been associated with altered sleep wave patterns, especially a lack of slow-wave sleep ([@B156]). A myriad of additional symptoms tends to accompany the disease, amongst them cognitive difficulties, depression, irritable bowel, irritable bladder, restless legs, dry mouth and eyes, and altered sense perception ([@B5]). Primary FMS is not accompanied by another chronic pain disorder, whereas secondary FMS develops as a co-morbidity of another dominant chronic disease, commonly an autoimmune disease ([@B59]). FMS prevalence among the adult population ranges from 0.8--5% worldwide, depending on the geographical area, case definition, and assessment method ([@B82]; [@B74]). FMS occurs in the pediatric population, generally beginning with the onset of puberty ([@B48]), but the highest prevalence is among middle-aged women. The female-to-male ratio ranges from 1:1 to 30:1, but a worldwide average is about 3:1 in both the pediatric ([@B48]) and adult populations ([@B149]).

Although FMS is classified as a musculoskeletal disease, the currently most accepted hypothesis of pathogenesis, central sensitization ([@B175]), is neurobiology-based and supported by empirical and impartial evidence ([@B115]; [@B169]). As the etiology and pathophysiology of FMS remain elusive, FMS treatment is directed to symptom management, which includes inhibition of an overreacting CNS ([@B114]). In general, 30% of the patients report a 30% improvement because of treatment ([@B59]). This modest efficacy suggests that the pharmacological treatment does not target the cause.

We hypothesize that FMS is a neuropathy-induced autoimmunity directed against nervous tissue. The autoimmune hypothesis provides a mechanistic explanation for the central sensitization hypothesis and thus the two hypotheses are compatible. Considering sex differences in the immune system, the autoimmune hypothesis may explain female predominance among FMS patients.

The autoimmune hypothesis emerged from the following observations. First, the epidemiological profile of FMS is similar to the one of autoimmunity as both peak among middle-aged women ([@B12]). Second, FMS co-occurs with a cluster of autoimmune diseases e.g., sicca syndrome, SLE, rheumatoid arthritis, irritable bowel syndrome, thyroiditis, interstitial cystitis/painful bladder syndrome, and restless legs syndrome co-occur. Autoantibodies 'specific' for aforementioned autoimmune diseases tend to be shared rather than unique. When they are detected in FMS, a corresponding autoimmunity is diagnosed and FMS is redefined as secondary FMS ([@B64]). Still, secondary FMS reveals autoimmune susceptibility ([@B20]; [@B50]; [@B56]). Specific antibodies for FMS have been reported ([Supplementary Table 1](#SM1){ref-type="supplementary-material"}), but they are neither consolidated nor generally accepted ([@B195]; [@B50]). Third, there is overlap in the clinical profile of FMS and certain autoimmune diseases, with respect to complex genetic and environmental risk factors. The latter include infections ([@B170]) and stress due to traumatic experiences ([@B165]). Stress and certain personality characteristics associate positively with autoimmune diseases, FMS, and other chronic diseases in retrospective studies with selected controls ([@B120]; [@B102]). But whereas stress and personality are considered precipitating factors or consequences in autoimmune diseases ([@B126]; [@B58]), they are interpreted as the cause in FMS ([@B102]) despite a lack of convincing evidence demonstrating a causal relation ([@B60]). Similarly, there is no convincing evidence that a certain personality causes pain ([@B133]). Fourth, although routinely screened inflammatory biomarkers in FMS samples (such as C-reactive protein levels and erythrocyte sedimentation velocity) tend to be within the normal clinical range, these and other immune markers are significantly different from the ones of healthy controls in a research setting ([@B84]; [@B200]; [@B145]; [@B124]; [@B9]; [@B26]). Although data on inflammatory biomarkers are not consisted among studies, they correlate weakly with clinical variables ([@B37]), or can be explained by comorbid conditions, the general impression is that chronic inflammation occurs in FMS ([@B37]). Similarly, routine leukocyte counts are within the normal range, but specific lymphocyte subgroups, not screened in clinical routine studies, are altered in FMS patients. Compared to age-matched healthy controls, female FMS patients had higher proportions of CD57+ natural killer cells (NK) (17.1% *vs*. 11.3%) and CD5+ B cells (6.46% *vs.* 2.5%) ([@B159]) but lower CD56+ NK ([@B103]). Case-control observational whole-genome expression studies among women revealed altered expression of immune pathways and markers of tissue destruction ([@B109]; [@B83]). These expression studies did not confirm gene polymorphisms that had been identified in genome association studies ([@B141]). The gene association studies often had a selection bias and did not clarify why the genetic susceptibility would only lead to a disorder later in life. In this respect, the *HLA* alleles ([@B18]; [@B203]) form an exception, as their impact depends on an interaction between genetic and environmental factors. *HLA* genes have an essential role in the immune system. Thus, the emerging picture is that a combination of genetic predisposition, a precipitating event (infections, trauma, autoimmune diseases or other reasons of necrosis) ([@B81]), and immune dysregulation due to psychological stress ([@B179]) may convert autotolerance or pre-existing occult autoimmunity into overt autoimmunity, but the autoreactive component remains elusive ([Figure 1](#F1){ref-type="fig"}). Importantly, though the precipitation event may be transitory, autoimmunity is a response of the adaptive immune system and is chronic. The sex bias in the immune system may explain the female preponderance of FMS.

![The autoimmune hypothesis for FMS. FMS complies with all mentioned risk factors of autoimmune disease, as well as with research biomarkers of an altered immune response. The missing pieces (indicated by "?") are the evidence of autoantibodies or autoreactive lymphocytes against nervous tissue.](fnins-13-01414-g001){#F1}

Why Does Central Sensitization Occur? {#S3}
=====================================

Pain perception not only depends on the pain stimulus, but also on the emotional and psychosocial state at a certain moment ([@B154]; [@B43]). Both human and animal studies reveal greater pain sensitivity among females than males for most pain modalities ([@B154]; [@B90]; [@B123]; [@B7]; [@B97]). The gender/sex bias in pain perception in various animal species denotes the importance of biological processes and thus sex differences therein. Unfortunately, pain studies aimed at other aspects than a sex or gender bias seldom report outcome variables according to sex or gender and only mention the proportion of males or females among study participants ([Supplementary Table 1](#SM1){ref-type="supplementary-material"}). As a consequence, although the sex-neutral neurophysiology of the pain pathway is well-described in several reviews ([@B11]; [@B204]; [@B142]; [@B89]) ([Figure 2](#F2){ref-type="fig"}), little is known about sex differences in pain processing, except for modulation by sex-related hormones ([@B180]; [@B190]; [@B6]). These biological aspects are at least as important as the psychological aspect ([@B44]). Though sex differences in functional pain processing in itself are interesting, for FMS the focus is on pathological pain processing, which has been explained with the central sensitization hypothesis.

![Neuroanatomy and chemistry of the central modulation of pain. Blue projections, incoming signals from 1st order neurons; red projections, ascending projections from 2nd order neurons toward thalamus (Thal) and cortical areas; yellow projections, projections for 3rd order neurons to cortical areas for awareness; green projections, descending projections that modulate the pain pathway. I-X, Reddit layers within the gray matter of the spinal cord; ↔, Integration of modulatory ascending and descending information in the dorsal horn Reddit laminae I-V (DH LI-V). 5-HT, serotonin; Aα, Aβ, Aδ y C, incoming nerves with decreasing levels of myelination; Amyg, amygdala; CC, cingulate cortex; CCKBR, cholecystokinin B receptor; CGRP, calcitonin gene-related peptide; DRG, dorsal root ganglia; Glu, glutamate; Ins, insula; LC, locus ceruleus; Na~*v*~, voltage-gated sodium channels; NE, norepinephrine; NGF, nerve growth factor; PAG, periaqueductal gray; RN, raphe nucleus; RVM, rostroventral medulla; S1, S, somatosensory areas 1 and 2; SP, substance P; TRP, transient receptor potential sensitive to nociceptive stimulus; μR, μ-opioid receptor with high affinity for enkephalins and beta-endorphin. Image based on ([@B185]; [@B1]; [@B139]).](fnins-13-01414-g002){#F2}

Central sensitization was originally described as an increased electrophysiological activity in the dorsal horn in both a polyarthritic ([@B125]) and a post-injury male rat model ([@B198]). Importantly, in both models a *peripheral* tissue injury triggered off alterations in dorsal horn neurons so that they augment pain signaling to normal input, even from low-threshold Aβ mechanoreceptors ([@B199]). Besides, in animal models, sex differences in pain processing, i.e., at a biological level, could only be detected *after neuropathy* ([@B173]) and involved the immune system.

Central sensitization has become the most accepted hypothesis to explain FMS mainly because peripheral sensitization due to autoimmunity is discarded because FMS does not comply with the following criteria of inflammation: (a) the presence of blood inflammatory biomarkers according to common clinical criteria, (b) responsiveness to non-steroid anti-inflammatory cyclooxygenase inhibitors. The former is debatable once research findings on immunological biomarkers (as mentioned in the previous section) are considered. The latter only indicates that FMS is not cyclooxygenase dependent, but discredits neither the involvement of other inflammatory and immune response pathways, nor does it nullify the possibility of neurogenic pain. Failure to comply with inflammatory criteria have not prevented the recognition of Graves' disease ([@B10]) and MS as autoimmune diseases ([@B110]). Furthermore, the need for inflammatory biomarkers does not apply to secondary FMS because the accompanying autoimmune disease will generate not only inflammatory biomarkers but also a continuous nociceptive input. In secondary FMS, the CNS changes appear to improve when nociceptive input is removed ([@B169]). The point is that the nociceptive input may also be present in primary FMS, but we are ignorant of it. FMS pain is said to be idiopathic, but the burning, nagging, excruciating pain that is characteristic of FMS ([@B73]) is consistent with neuropathy. Histopathological studies have been performed on muscular and connective tissues ([@B73]), but not on dorsal root ganglia and central nervous tissue along the pain pathway. History teaches that myasthenia gravis was considered an idiopathic paralysis. Only after having established the involvement of the immune system were pathological immune infiltrates observed in muscle tissue ([@B72]). There are indications that neuropathy is present in FMS patients ([@B186]; [@B152]; [@B99]). FMS pain may reflect a neuropathy of a currently unknown etiology, which is compatible with the central sensitization hypothesis. [@B104] reviewed neuroplasticity at the molecular and cellular level to explain central sensitization in pain hypersensitivity. They underscore the fundamental contribution of an inflammatory or neuropathic event to initiate the central sensitization.

Rat spinal cord slices exposed to pro-inflammatory cytokines display patch-clamp recordings that are congruent with the central sensitization hypothesis ([@B87]), suggesting that the immune system plays a role; but, as is the case too often, proper controls were missing. A mouse study revealed the essential role of the immune sensor TLR8 in the maintenance of neuropathic pain. After nerve injury, TLR8 levels increased in the small IB4+ neurons in the dorsal root ganglia and in the ipsilateral dorsal horn. Subsequent intrathecal or intradermal injection of TLR8 agonists (VTX-2337 and miR-21) induced mechanical allodynia, and increased excitability of neurons in the dorsal root ganglia, accompanied by the expression of inflammatory mediators like interleukin 1 beta, interleukin 6, and tumor necrosis factor alpha. These effects were absent or reduced in *TLR8* knock-out mice ([@B205]). Aforementioned study did not report on sex differences, but in humans, *TLR8* is an X-linked gene that may escape X-inactivation leading to a dosage difference between men and women ([@B187]). TLR8 is especially important because of its pro-autoimmunity potential ([@B143]). A recent study with BALB/c and C57BL/6 mice suggests that circulating immunoglobulin G (IgG)-type immune complexes may directly mediate hyperalgesia at the level of dorsal root ganglia ([@B15]) where macrophages and neurons have receptors for IgG1 and IgG2b ([@B15]). If this mechanism were to be confirmed in humans, it would make women more vulnerable, because women are more inclined to humoral adaptive immune responses than men (see Section Sex Differences in the Immune System). Another mouse study revealed sex differences in pain processing. Intrathecal stimulation of the immune sensor of danger TLR4 induced mechanical allodynia in male, but not in female mice. At a cellular level, microglia in the spinal cord proliferated in both sexes after peripheral nerve injury, but only male microglia upregulate the immune sensor of danger, P2RX4 ([@B119]). P2RX4 detects nucleotides, mainly ATP, released after CNS stress or injury ([@B31]). Activation of P2RX4 receptors leads to release of pro-inflammatory interleukin 1β and brain-derived neurotropic factor, which promote pain hypersensitivity. The inhibition of microglia in the spinal cord reversed allodynia only in male rodents. The female pain process requires more investigation ([@B173]). As for humans, sex-biased pain because of knee osteoarthritis could be explained by differences in immune signaling molecules, interleukin 8 and monocyte-chemoattractant protein-1 ([@B97]). Interleukin 8 is one of the immunological biomarkers most consistently associated with FMS ([@B96]). Thus, sex differences in pathological pain processing mainly involves immune sensors and immune cells. And as we will see in Section "Sex Differences in the Immune System," the immune system presents sex differences.

Besides, the sex bias of central sensitization remains to be elucidated. We hypothesize that autoimmunity directed to the CNS, either toxic or stimulatory, explains not only central sensitization, but also the female predominance of FMS and the lack of peripheral inflammatory biomarkers.

Why Is Slow-Wave Sleep Missing? {#S4}
===============================

The neurobiology of sleep and the regulation of the daily sleep-wake cycle have been reviewed with a clinical perspective by [@B38]. Gender and sex differences in sleep health have been recognized but major gaps continue to exist is areas of sleep regulation, the epidemiology of sleep problems, diagnosis and treatment ([@B116]). Two sexually dimorphic areas, the preoptic area and suprachiasmatic nucleus ([@B67]; [@B68]) have been associated with sleep problems ([@B38]). However, it seems that the sexual dimorphic nucleus of the preoptic area is dedicated to sexual and parental behavior ([@B157]) rather than to sleep regulation. More recently, another brain area, the anterior cingulate cortex, has been involved in both primary insomnia ([@B201]) and FMS ([@B79]), but neither study analyzed sex differences. Still, sleep differs between men and women and may contribute to a sex-biased risk for sleep disorders ([@B116]) and, consequently, for FMS.

Polysomnography studies have revealed a variety of sleep disturbances in FMS patients ([@B25]). Especially, the phase of deep sleep is reduced and otherwise affected. Instead of the synchronized and therefore high-amplitude slow waves characteristic of the δ rhythm, desynchronized low-amplitude high-frequency waves characteristic of the α rhythm interfere, generating a pattern known as α-δ sleep ([@B25]). Deep sleep is considered to be important for memory consolidation and restoration processes. Abnormal deep sleep and other sleep disturbances may contribute to the development of chronic pain ([@B42]) and FMS ([@B127]).

Taking together the difficulty to maintain slow-wave sleep and the peak symptomology upon awakening, it seems as if the regulation of the different sleep phases may be involved. The well-known somnogenic adenosine seems to have a special role in the regulation of the slow-wave sleep phase as revealed by studies with male C57BL/6 mice ([@B138]). Extracellular adenosine accumulation activates the adenosine A~1~ receptor which inhibit arousal and induces slow-wave sleep. Another adenosine receptor, A~2*A*~ receptor, can induce slow-wave sleep, but can be overruled by a motivation stimulus, like hunger or stress (Lazarus, et al. 2019). These receptors are found in the nucleus accumbens. Thus, the nucleus accumbens, already known for being part of the reward circuit, has a role in the control of the slow-wave sleep phase via adenosine receptors. A variety of enzymes and adenosine and nucleotide transporters in both neurons and astroglia are important for extracellular adenosine levels in the micro-environment of the nucleus accumbens. Interestingly, the A~2*A*~ receptor also regulates naive T cell development in the thymus and its maintenance in the periphery ([@B23]). In summary, adenosine, associated metabolites and involved enzymes and transporters may be important in slow-wave sleep and FMS, but further research is necessary.

Autoimmune Diseases: a Confused Immune System {#S5}
=============================================

Activation and Tolerance in the Immune System {#S5.SS1}
---------------------------------------------

The definition of autoimmune disease is relatively straightforward: a "disease that results when the immune system \[..\] mistakenly attacks the body's own tissues" ([@B194]). In practice it is more complicated as non-symptomatic healthy persons tend to have autoantibodies ([@B181]), which are eliminated before doing harm ([@B132]). For a disease to be classified as autoimmune there must be *detectable* autoantibodies or autoreactive T-cells in amounts *sufficiently higher than non-symptomatic controls* and they must *explain* the symptoms or *present a strong epidemiological association* with the symptoms. These requirements are fulfilled for all recognized autoimmune diseases, most often because of autoantibodies whether or not in combination with immune infiltrates ([@B33]). In autoimmune diseases that cluster with FMS, such as rheumatoid arthritis, Sjögren's syndrome, and SLE, specific and diagnostic autoantibodies have been identified. Autoantibodies against cryptic nuclear, cytoplasmic and proteolipid protein antigens are shared in various autoimmune diseases ([@B177]; [@B40]).

Instead of being due to one specific cause, autoimmune diseases develop when risk factors accumulate. Central to autoimmune diseases is the loss of tolerance to autoantigens. Tolerance of the immune system is the non-activation of the immune response. Upon contact with a substance, particle or pathogen our defense system must decide to attack or to be tolerant. Essential for this decision is recognition, which is different for the three levels of protection of our defense system.

The first line of defense is a biophysicochemical barrier that does not need activation nor recognition. The second level of protection is provided by the innate immune system, a fast-reacting system without memory. Memory is not required as similar cell types or humoral factors share the same receptors for dangers and will attack the same patterns of danger. This in contrast with the third level of protection, provided by T lymphocytes and B lymphocytes. Lymphocytes have unique receptors, so that few will react upon a pathogenic invasion. T lymphocytes are activated by antigen presenting cells of the innate immune system, that provide instructions according to the danger pattern that were encountered. When selected and activated, lymphocytes generate a clone for future memory and effector cells that are either cytotoxic (Tc) or differentiate in a variety of mediators (helper T cells, Th) that potentiate different components of the innate and adaptive immune systems, while effector B lymphocytes (B) become plasma cells (plasma) that produce antibodies. If a tolerance response is erroneously converted into an active immune response, the memory of the adaptive immune response will respond with immune hypersensitivity upon future challenges.

### Activation and Tolerance in the Innate Immune System {#S5.SS1.SSS1}

The tolerance mechanism of the innate immune system is passive; i.e., the innate immune system is only activated upon the detection of a limited number of non-self molecular patterns associated with pathogens (PAMPs) or endogenous damage (DAMPs). Hereto, innate immune cells share a limited set of PAMP recognition receptors. Depending on the pattern recognized, an appropriate action is initiated ([@B66]). Everything that is not a PAMP or DAMP is automatically tolerated by the innate immune system. In general, loss of auto-tolerance is not due to breaches of tolerance of the innate immune system.

### Activation and Tolerance in the Adaptive Immune System {#S5.SS1.SSS2}

Both recognition/activation and tolerance are more complex in the adaptive immune system ([@B163]). The adaptive immune system is able to recognize a huge number of structures (known as antigenic determinants or epitopes) because of an enormous variety of specific receptors, T-cell receptors (TCRs) and B-cell receptors, that differ among lymphocytes. As a consequence, when a noxious antigen invades the body, only few specific lymphocytes will react. Clonal proliferation of a triggered lymphocyte generates a specific 'army' composed of effector lymphocytes (to eliminate current danger) and memory lymphocytes to provide a faster and stronger immune response for a future challenge with the same antigen.

As the specificity of the TCR and B-cell receptors is generated at random, these receptors may recognize harmless xenoantigens and autoantigens ([@B91]). To avoid allergies and autoimmune diseases, the adaptive immune system has three control mechanisms: (a) central tolerance, (b) peripheral tolerance, and (c) major histocompatibility complex-restricted activation of T cells, i.e., a T cell can only be activated when its cognate antigen is presented by a major histocompatibility complex molecule.

### HLA Presents Protein-Associated Epitopes to the Adaptive Immune System {#S5.SS1.SSS3}

In humans, the major histocompatibility complex is known as HLA. The HLA genes of class I (*A, B*, and *C*) and II (*DP, DQ*, and *DR*) are the most polymorphic genes of the human genome and provide a molecular identity to an individual. All nucleated cells of the human body express HLA-I, although leukocytes express them in larger amounts, while HLA-II is expressed by specialized antigen-presenting cells. HLA-I presents antigens to CD8 + cytotoxic T cells, while HLA-II presents antigens to CD4+ helper T cells (Th) ([@B66]). As antigen presentation to T cells is HLA-restricted, only body-own cells will be protected. The polymorphism of the HLA molecules has an impact on the quality of the immune response. Certain HLA-antigen complexes facilitate the immune response of an individual and others not. Thus, the individuals of a population differ in their protective capacity and their susceptibility to autoimmune diseases. The antigen presentation process is designed for large proteins, preferentially in a particulate presentation. Therefore, electrolytes, sugars, lipids (e.g., sex hormones), nucleic acids, peptides (e.g., neuropeptides), and other small molecules (e.g., neurotransmitters) are passively tolerated. On the other hand, tolerance to protein autoantigens is an active, energy-consuming, and highly controlled process with central and peripheral mechanisms.

### Mechanisms of Central Tolerance {#S5.SS1.SSS4}

Central tolerance is established in the primary lymphatic organs, most importantly, in the thymus, where developing T cells or thymocytes reorganize their genome at random to express a unique TCR, either xenoreactive or autoreactive. The thymic epithelial cells function as 'teachers' of the thymocytes. Hereto, the thymic epithelial cells express "AIRE)," a transcription factor that facilitates the expression of organ-specific autoantigens in the thymus. The autoantigens are presented in combination with HLA to the thymocytes. To survive, thymocytes should recognize HLA (positive selection) but not recognize autoantigens (negative selection). Simplified, autoreactive thymocytes have two fates ([@B91]): (1) they die by apoptosis, in case of a strong and long antigen-TCR interaction, and (2) they become regulatory T cells (nTreg), when the antigen-TCR interaction is of intermediate strength and length ([@B8]; [@B137]). Thymocytes that do not react with autoantigens or only shortly and with low-affinity are liberated as naïve Th or cytotoxic T cells to protect against danger in the periphery.

As not all autoantigens are expressed in the thymus in sufficient amounts, autoreactive naive T cells may circulate in the periphery, a phenomenon known as ignorance.

### Mechanisms of Peripheral Tolerance {#S5.SS1.SSS5}

Peripheral tolerance complements central tolerance by any of the following mechanisms: (1) clonal deletion of autoreactive T cells by apoptosis, (2) the peripheral induction of Treg (iTreg) under the influence of transforming growth factor beta, (3) anergy, i.e., a reversible inactive state of the T cell when the antigen presenting cells do not provide a costimulatory signal ([@B129]), and (4) ignorance, i.e., the amount of auto-antigen is insufficient to induce either tolerance or an immune response. The choice for any of these tolerance options depends on the abundance, strength and duration of the TCR-antigen interactions, but it is conditioned by the absence of a danger signal. As the T cell has no information about the type of danger recognized by its at-random-generated TCR, this information is provided by the antigen presenting cell. Depending on the type of PRR activated the antigen presenting cell provides a costimulatory signal and instructions about the desired type of response (Th1, Th2, or Th17 response) via cytokines ([@B85]). Apart from these major tolerance processes, immune responses are fine-tuned by many stimulatory, inhibitory, and modulatory molecules (e.g., CD5) ([@B167]) and cells, e.g., NKT cells ([@B28]) within the immune system, as well as neuroendocrine peptides and hormones beyond the immune system ([@B21]). In summary, the adaptive system mainly attacks large protein (\>10 kDa) antigens and tolerance to large self-proteins is a complex and highly regulated process.

Loss of Tolerance and Development of Autoimmune Diseases {#S5.SS2}
--------------------------------------------------------

Tolerance may be breached for any of the following reasons or a combination of them. First of all, molecular mimicry between an auto-antigen and a pathogenic antigen may confuse the immune system. A well-known example is the Guillain-Barré syndrome due to autoantibodies directed to peripheral nerves because of cross-reaction between nerve autoantigens and certain pathogen antigens, especially *Campylobacter jejuni*, Epstein-Barr virus, cytomegalovirus ([@B75]).

Secondly, bystander autoantigens that are presented in combination with danger signals due to concurrent infections or physical trauma may overcome tolerance, which may play a role in the development of autoimmune diseases ([@B49]). The bystander mechanism may also explain how a 'founder' or primary autoimmune disease may lead to secondary autoimmune diseases. Cell lysis due to inflammation of the primary autoimmune disease liberates multiple cryptic autoantigens (mitochondrial antigens, phospholipid antigens, ribonucleoproteins, and other cytoplasmic autoantigens) that provide DAMPs. And the cycle repeats itself: novel autoantigens in combination with danger signals may lead to multiple autoreactive clones of lymphocytes. Cryptic autoantigens liberated during necrosis are shared by different autoimmune diseases ([@B177]). Although the etiology is not proven, latent viral infections associate with MS ([@B192]). A reactivating latent viral infection may cause not only minor damage to nervous tissue but also a breach in tolerance either by molecular mimicry or the bystander effect. Multiple cryptic autoantigens are liberated due to repeated tissue damage, so that polyautoimmunity develops. In MS, oligoclonals are directed against a mixture of autoantigens of cellular debris ([@B19]). Initially, MS can be more or less controlled by interferon treatment ([@B131]), which has antiviral activity, until the polyautoimmune disease has become autosustainable and the relapsing-remitting MS patient turns into a secondary-progressive MS patient. In MS, just as in FMS, inflammatory biomarkers of the blood tend to be within the normal range ([@B110]) as the inflammatory process occurs localized, i.e., behind the blood-brain barrier. Aforementioned process probably plays a role in many autoimmune diseases but have been recognized for only a few. The clinical importance is high because antimicrobial treatment may resolve the initial infection, once the autoimmune disease has developed it may be too late ([@B130]). Alternatively, it explains why steroid anti-inflammatory treatment worsens ([@B27]) rather than improves the symptoms.

Thirdly, there is a genetic predisposition for most autoimmune diseases, especially in the HLA genes, probably as a consequence of affinity issues between the HLA molecule and the presented antigen ([@B17]). HLA-DR2, DR3, DR4, DQ6, and DQ8 are associated with SLE, sicca syndrome, and rheumatoid arthritis ([@B117]). Furthermore, gene polymorphisms in complement factors may diminish autoantibody clearance ([@B113]).

Fourthly, CD5 expression fine-tunes the adaptive immune response in a complex way ([@B167]). CD5 on T or B lymphocytes may either facilitate or inhibit an adaptive immune response depending on avidity issues ([@B32]). In general, CD5+ B cells have been related with increased susceptibility for autoimmune disease, while the opposite applies to T cells ([@B182]; [@B146]; [@B61]).

Fifthly, stress dysregulates the immune system ([@B165]). Acute stress enhances catecholamines and circulating leukocytes, which facilitates a stronger immune response. Chronic stress, on the other hand, is immunosuppressive. The stress hormone cortisol diminishes leukocyte numbers and suppresses leukocyte function ([@B30]). The stress hormones epinephrine and cortisol induce a rapid leukocyte redistribution. Although the exact mechanisms of this phenomenon remains to be elucidated, clinical and epidemiological data convincingly and consistency reveal an association between chronically stressed people and vulnerability to and resurgence of infections and autoimmune diseases ([@B153]).

Sixthly, the immune response is age dependent ([@B36]) and age has is a risk factor for loss of central tolerance. In over 60% of autoimmune cases, the onset of symptoms was in the fourth and fifth decade of life, with a median onset at 37.5 years of age ([@B39]). A detection bias may play a role in the age effect. Autoimmune disease may not be apparent at the onset, because the progression is slow and their biochemical, physiological or visual detection not obvious. For example, Sjögren syndrome, an autoimmune disease affecting the glands, becomes apparent in older individuals, because destruction of the glands is slow and symptoms of dryness are only experienced when most of the glands are destroyed ([@B69]). Importantly, the most essential organ for central tolerance, the thymus, undergoes profound age-associated atrophy ([@B111]). Thymic decline is clearly associated with the presence of sex steroids ([@B63]).

And finally, being female is a risk factor for many autoimmune diseases. A sex bias in the immune system is well-documented and will be described in more detail in the next section.

The unfortunate co-occurrence of aforementioned risk factors elicits an autoimmune disease. It is important to highlight that the initial trigger may be transitory, but the induced autoimmune response is chronic due to the memory of the adaptive immune response. Aforementioned risk factors all apply to FMS (see Section Fibromyalgia: Introducing the Autoimmune Hypothesis and [Figure 1](#F1){ref-type="fig"}).

Sex Differences in the Immune System {#S6}
====================================

The burden of infectious diseases and the incidence of cancer, allergies, and autoimmune disease differs between men and women. Though this phenomenon can be partially explained by a differential exposure of men and women to environmental risk factors, sex differences in the immune system are evident and well-known. The expression of many immune system-associated proteins and activation of immune cells differs between the sexes as have been reviewed elsewhere ([@B93]; [@B151]). Well-known is a Th1 bias in male and a Th2 bias in female ([@B93]). The latter facilitates the natural passive transfer of immunity from mother to fetus, as immunoglobulins G are able to pass the placenta to protect the fetus. Furthermore, as of adulthood, the number of innate and adaptive leukocytes is higher in females than in age-matched males ([@B188]), except for Treg and innate lymphoid cells, including NK, which are more abundant in males ([@B93]). NK have functions beyond cytotoxicity including an important role in the regulation of immune homeostasis and inflammation ([@B193]). During aging, the diverse NK population changes gradually; the proportion of immunoregulatory CD56^*hi*^ NK diminishes in favor of highly differentiated cytotoxic CD57^+^ NK. This redistribution may explain functional changes in NK cells with healthy aging ([@B47]). The dysregulation of NK and NKT cells is associated with allergies and autoimmune diseases ([@B134]; [@B178]). Here, we highlight that the cellular immune response tends to predominate in men and the humoral immune response in women. Furthermore, adult men tend to have more immunoregulatory cells than women.

Differential Effect of Sex Hormones on Leukocyte Behavior {#S6.SS1}
---------------------------------------------------------

Sex hormones differentially influence the behavior of leukocytes. There is a differential distribution of sex hormones receptors among leukocytes. For example, CD4+ T cells have high levels of the estrogen receptor alpha but low estrogen receptor β levels, whereas the opposite applies for Treg. CD8+ Tc have low expression levels for both types of estrogen receptors, whereas NK express both receptors highly. In mice, high estrogen levels signal via estrogen receptor α and induce antiviral type 1 interferon and NK cells, as well as Treg. Signaling via estrogen receptor β has opposing effect and results in diminished Treg activation. Furthermore, the transmembrane G protein-coupled estrogen receptor, which induces rapid signaling is highly expressed by certain leukocytes (CD4+ Th, Treg, B cells, and macrophages) ([@B94]). Estrogen diminishes neutrophil infiltrates and protects against the harmful effects of the innate response ([@B166]; [@B155]). Progesterone and testosterone promote monocyte recruitment and an androgen receptor antagonist reduced monocyte recruitment ([@B184]; [@B176]). On the other hand, testosterone treatment reduced immunoglobulin M and immunoglobulin G production and as such diminishes peripheral humoral adaptive immunity ([@B86]). The effects of sex hormones are complex because of opposing effects depending on concentration ([@B70]), the variety in metabolic forms that modulate the immune response, and relative concentrations of various sex hormones. Our intention is not to unravel the intricate interactions between the sex hormones and immune system, but to highlight its existence. The area requires more investigation, but it seems that testosterone procures central tolerance. Taken together, testosterone and progesterone downregulate peripheral (humoral) adaptive immunity, but facilitate peripheral innate immunity ([@B71]; [@B101]), whereas the opposite applies for estrogen as it is associated with peripheral innate immune suppression, stronger humoral responses, and weaker central tolerance ([@B98]).

Sex Differences in Immune Tolerance {#S6.SS2}
-----------------------------------

As mentioned above, the thymus has an essential role in central tolerance. Thymic involution is different between the sexes, especially after the onset of puberty, with a more prominent decline in males than in females, so that the adult female thymus contains more thymocytes and has a higher thymic output than the male thymus ([@B53]). However, the T cells liberated from the female thymus may have been less well 'educated' as the female thymic epitheliocytes express less AIRE and fewer autoantigens (mRNA and protein) than the male ones ([@B34]). Low expression levels of AIRE associate with autoimmune disease ([@B161]; [@B108]).

The sex hormones, estrogen and dihydrotestosterone (the main active metabolite of testosterone), regulate AIRE expression in opposite directions. At physiological doses, estrogen diminishes AIRE expression, whereas dihydrotestosterone increases AIRE expression ([@B34]). Dihydrotestosterone treatment in an experimental animal model of MS, upregulated AIRE and tissue-specific antigen expression in the thymus, improved negative selection of autoreactive T cells, and diminished the severity of autoimmune disease ([@B206]). A cross-sectional population-based study revealed that a higher estradiol/testosterone ratio associated significantly with autoimmune thyroid disease among Chinese men ([@B24]). Interestingly, a clinical phase I/II pilot study among 12 female FMS patients revealed that a 28-day treatment with testosterone gel significantly decreased pain, stiffness, and fatigue ([@B196]). Altogether, the efficacy of the thymus depends strongly on age and sex hormones. Male sex hormones seem to compensate for thymic involution with an increased AIRE expression, whereas female sex hormones contribute to diminished tolerance and increased vulnerability to autoimmune diseases.

Sex Chromosomes and Immune-Associated Genes {#S6.SS3}
-------------------------------------------

The major genetic difference between men and women are the sex chromosomes. Men are XY, whereas women are XX. To enable the pairing of the X and Y chromosomes during male meiosis, small pseudo-autosomal regions are present at the extremes of both the X and Y chromosome. In the pseudo-autosomal regions, the X and Y chromosomes encode the same genes ([@B118]). For non-pseudoautosomal region genes, males will express the genes of the unique X chromosome, whereas female cells perform at random X inactivation as a dosage compensation mechanism. X inactivation is clonally maintained and generates a functional mosaic organism for X chromosome-encoded genes ([@B158]). Importantly, X-chromosome inactivation is not an all-or-non-phenomenon; about 10--15% of the X chromosome-encoded genes escape X-inactivation in humans, and a mouse model of accelerated aging revealed increased reactivation with age ([@B14]).

Although it has been stated that the X chromosome encodes a disproportionally large number of immune-associated genes ([@B16]), so far no scientifically sound supporting evidence has been published. Still, the increased susceptibility for immune hypersensitivities of men with Klinefelter's syndrome (XXY) or women with Turner syndrome (X-) reveals the importance of dosage of X-linked immune system-associated genes ([@B128]; [@B162]). An elegant study that used the four genome model (XX*~*Sry*~*+, XY*~*Sry*~*+, XX, XY*~*Sry*~*^--^) in two gonadectomized mouse models for autoimmune disease demonstrated a dosage effect of the X chromosome in SJL mice. Interestingly, the dosage effect was not observed in C57BL/6 mice ([@B171]). The genetic background of C57BL/6 mice contrast with the one of SJL mice in terms of susceptibility for murine cytomegalovirus and autoimmune disease. In contrast to SJL, C57BL/6 has a bias toward a Th1 response and high NK activity ([@B164]; [@B172]). This cellular immune response protects against viral infections.

Two X-linked genes are especially associated with humoral autoimmune disease to cryptic antoantigens. *TLR7* and *TLR8* (both in band Xp22.2) encode endosomal immune sensors that sense microbial and endogenous RNA ([@B187]). *TLR7* expression displays a dosage disequilibrium in biallelic B lymphocytes of women and men with Klinefelter's syndrome. These biallelic B lymphocytes switch more easily to IgG ([@B174]), which is consistent with SLE symptom severity in TLR7 + as compared to TLR7-deficient C57BL/6 mice ([@B29]). In a 564Igi mouse model of SLE, a dosage difference in TLR8 determined the sex bias in anti-RNA IgG antibodies, which were higher in female than male mice ([@B187]). 564Igi mice are especially susceptible to autoimmunity because of diminished somatic hypermutation ([@B121]). The release of miR-21 due to neuropathy stimulates TLR8 signaling in the dorsal root ganglia, which leads to hyperexcitability and pain ([@B205]). Importantly, TLR8 activation can reverse tolerant Treg into aggressive forms ([@B143]). Thus, X-linked RNA immune sensors may be activated in neuropathy and favor autoimmunity rather than immune tolerance.

Autoimmunity to the Nervous System. What Triggers It Off? {#S7}
=========================================================

The CNS used to be considered an immunoprivileged organ, and therefore little susceptible to autoimmune issues. But this viewpoint has changed over the last two decades upon the detection of autoantibodies against a variety of nervous system autoantigens. As expected, most autoantibodies are directed against large, complex protein autoantigens ([Table 1](#T1){ref-type="table"}) rather than against small non-protein molecules. Currently, among patients with mental illnesses, the serum prevalence of autoantibodies against nervous tissue antigens is 11--17%, which may be an underestimation ([@B52]).

###### 

Autoantibodies against nervous tissue autoantigens.

  **Autoantibody target**                            **Normal function**                                                     **Clinical anomaly**
  -------------------------------------------------- ----------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Membrane glycolipids**                                                                                                   
  GM1, GQ1b                                          Ganglioside, Schwann cell                                               Miller-Fisher syndrome, Bickerstaff encephalitis, Guillain-Barré syndrome (1)
  MOG, GM, Non-defined                               Myelin                                                                  Multiple sclerosis, myelin destruction; unmyelinated fibers (2)
  **Neurotransmitter receptors**                                                                                             
  Presynaptic VGCC                                   Voltage-gated calcium channels                                          Lambert-Eaton syndrome; weak muscles (3)
  Postsynaptic nAChR                                 Nicotinic acetylcholine receptor                                        Myastenia gravis (4)
  AMPAR                                              Ionotropic glutamate receptor                                           Limbic encephalitis, seizure, psychosis (5)
  GluA3/GluR~3~                                      Ionotropic AMPAR-type glutamate receptor                                Rasmussen encephalitis, unihemispheric brain atrophy (5, 6)
  GluN1                                              Ionotropic NMDAR-type glutamate receptor                                Anti-NMDAR encephalitis (psychosis, seizure (5, 6))
  mGluR1                                             Metabotropic glutamate receptor, increase \[Ca^2+^\]~*intracellular*~   Paraneoplastic cerebellar ataxia (5, 6)
  mGluR5                                             Metabotropic glutamate receptor, release K^+^                           Limbic encephalitis, Ophelia syndrome (5, 6)
  GABA~*A*~R                                         Ionotropic GABA receptor; fast-reacting                                 Encephalitis, seizure (5)
  GABA~*B*~R                                         Metabotropic GABA receptor; slow-reacting                               Limbic encephalitis (5)
  GlyR                                               Glycine receptor                                                        Progressive encephalomyelitis with rigidity and myoclonus (PERM); stiff-person syndrome (5)
  D~2~R                                              Pre-synaptic modulatory or post-synaptic dopamine receptor              Limbic encephalitis, seizure, psychosis (5)
  **Voltage-gated sodium channels**                                                                                          
  Na(x)                                              Sodium-sensor and channel                                               Hypernatremia, neoplasia associated (7)
  **Transmembrane proteins or associated protein**                                                                           
  AQP4                                               Aquaporin-4, water channel abundant in astrocytes                       Neuromyelitis optica (8)
  CASPR2                                             Contactin-associated protein-like 2, transmembrane on axons             \- (Limbic) encephalitis, - neuromyotonia, muscle spasms and pain, excessive sweating and disordered sleep - Morvan syndrome - Isaac syndrome, acquired neuromyotonia - fasciobrachial dystonic seizures (3, 5)
  VGKC                                               Voltage-gated potassium channel                                         
  LGI1                                               Leucine-rich glioma                                                     
  DNER                                               Delta and Notch-like epidermal growth factor-related receptor;          Paraneoplastic cerebellar degeneration (5)
  DPPX                                               Dipeptidyl-peptidase-like protein 6                                     Encephalitis with diarrhea (5)
  DCC                                                Netrin receptor; involved in axon guidance                              Neuromyotonia (5)
  IgLON5                                             Neural cell adhesion molecule                                           Non-rapid-eye movement and rapid-eye movement parasomnia with abnormal movements and sleep breathing disorder (5, 9)
  Neurexin                                           Presynaptic synapse-facilitating transmembrane protein                  Encephalitis (5)
  **Cytosolic protein**                                                                                                      
  GAD65                                              Glutamate decarboxylase 65 kD isoform; conversion Glutamate to GABA     Associated with limbic encephalitis, schizophrenia, stiff-man syndrome, diabetes type 1, autoimmune thyroidits, pernicious anemia (3)
  GFAP                                               Glial fibrillary acid protein                                           Diabetes type 1 (10)
  49 kD pituitary cytosolic protein                  Autoimmune hypophysitis (11)                                            
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After neuropathy (due to infection or a lesion), intracellular macromolecules that previously were encrypted autoantigens may be exposed and targeted by autoantibodies ([@B183]). The latter probably occurs in MS, where oligoclonals target ubiquitous intracellular proteins ([@B19]). Oligoclonal bands are interpreted as immunoglobulins that are produced intrathecally, i.e., inside the CNS ([@B110]). Oligoclonal bands occur in 95% of MS patients ([@B54]). Other targets of MS autoantibodies are myelin-associated autoantigens ([@B107]) and viral antigens ([@B192]). Although no specific virus is considered to be the causative agent of MS, viruses may be direct or indirect risk factors. The latter via molecular mimicry and/or bystander activation ([@B191]) as described in Section "Loss of Tolerance and Development of Autoimmune Diseases." Various psychiatric diseases are considered to be caused by either an autoimmune process or an infection ([@B168]; [@B35]). We propose that in many cases both occur; the infection would be the initiation event and autoimmunity a consequence. Still they may occur simultaneously, especially when involving opportunistic pathogens. A variety of herpes viruses are opportunistic, pandemic, and neurotropic. Depending on the geographic location, 40--100% of the adult population is infected. A primary infection establishes a lifelong latent infection, which reactivates intermittently without obvious disease symptoms, except for immunocompromised persons. Stress may be a trigger for 'asymptomatic' reactivation. Among herpes viruses, cytomegalovirus seems especially apt to alter the immune response into autoimmunity ([@B2]; [@B189]; [@B55]), while Epstein-Barr virus-transformed lymphocytes tend to produce autoantibodies ([@B46]). In case FMS etiology involves neuropathy by reactivating latent pathogens, the unresponsiveness to corticosteroid treatment is understood. Considering the heterogeneity of FMS patients, other infections or neuropathic events should not be ruled out as possible triggers of autoimmunity.

The Missing Piece: Evidence of Autoimmune Components Specific for FMS {#S8}
=====================================================================

Autoantibodies against intracellular antigen, nervous and muscle tissue have been reported in FMS patients ([Supplementary Table 1](#SM1){ref-type="supplementary-material"}), but their role in FMS pathogenesis is controversial. We suggest to screen nervous tissue involved in the pain pathway, both CNS (including the pituitary and pineal glands) and peripheral nervous tissue (dorsal root ganglia) with patient samples (blood and CSF), to complete the missing evidence ([Figure 1](#F1){ref-type="fig"}). A variety of conceptual and technical issues may complicate the detection of autoantibodies. The lack of tissue lesions should not be interpreted as the absence of autoimmunity, as autoantibodies may be stimulatory as in Graves' disease ([@B202]). Screening of autoantibodies should not be limited to blood, as autoantibodies or oligoclonals may be limited to CSF when neuropathic symptoms predominate (Luzzio and Dangond). Furthermore, pleocytosis of leukocytes in CSF should be evaluated. Autoantibody screening on certain tissues may yield false negatives when the autoantibodies are directed against other tissues than the ones that are screened. Screening on animal tissues may yield false negatives when the human autoantigens are sufficiently different from the animal forms. Screening on fixed tissues may yield false negatives because the appropriate antigen retrieval method was not applied. Also, the autoimmune response may be cellular rather than humoral. A conceptual or interpretation issue are prodromal autoantibodies; tissue destruction mediated by prodromal autoantibodies remains asymptomatic until the overcapacity of the targeted organ has been lost ([@B4]; [@B62]; [@B57]). During the prodromal period, autoantibodies run the risk to be interpreted as false positives. Longitudinal follow-up studies of patients with prodromal autoantibodies would be interesting. And finally, because of the heterogeneity among FMS patients, a certain etiology or pathogenesis may be limited to a subgroup of FMS patients ([@B76]; [@B148]). The worst scenario would be that the detected pathogenesis is discarded because it does not apply to a sufficiently high proportion of FMS patients. To avoid this situation, stratification or clustering of FMS patients is recommendable. Despite the aforementioned, the challenge is not impossible; the detection of anti-IgLON5 is exemplary ([@B160]). We recommend a similar screening technique to verify whether an autoimmune process is involved in the pathogenesis of FMS.

Conclusion {#S9}
==========

The clinical profile of FMS displays a strong overlap with certain autoimmune diseases. In fibromyalgia, physical or mental stress may constitute a precipitating factor or a consequence rather than a cause, similar to the situation in autoimmune diseases. Stress may debilitate the immune system and allow for reactivation of a latent (viral) infection, which may cause neuroinflammation or neuropathy and facilitate autoimmune phenomena. However, different from most autoimmune diseases, common clinical serum markers of inflammation are within the normal range in FMS. Still, altered immunological biomarkers, especially CD57 and IL-8 levels, are compatible with a viral infection or autoimmune mechanism. Sex differences in the immune system would explain a sex bias in FMS prevalence. If convincing evidence for an autoimmune process were detected for FMS, diagnostic tests and effective therapies could be developed. Blood and CSF should be screened for autoantibodies and/or autoreactive lymphocytes. Screening for autoantibodies directed to peripheral nervous tissues and CNS should include dorsal root ganglia, the spinal cord, pituitary gland and pineal gland, should be screened as possible targets for autoantibodies and autoreactive lymphocytes.
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AIRE

:   autoimmune regulator

CNS

:   central nervous system

CSF

:   cerebrospinal fluid

FMS

:   fibromyalgia syndrome

HLA

:   human leukocyte antigen

MS

:   multiple sclerosis

NK

:   natural killer cell

SLE

:   systemic lupus erythematosus

TCR

:   T cell receptor

TLR

:   Toll-like receptor

Th

:   helper T lymphocyte

Treg

:   suppressor T lymphocyte.
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